II vigabatrin in 'add-on' nelle epilessie farmacoresistenti. Sette anni di esperienza: Studio retrospettivo su 220 casi

Translated title of the contribution: Vigabatrin in add-on therapy in drug-resistant epilepsies. Seven years' experience: Retrospective study on 220 patients

A. Mariniello, S. Morena, V. Loreto, B. Muraca, C. Nocerino, L. Bilo, R. Meo, P. Ruosi, A. Estraneo, O. Mecarelli, M. R. De Feo, S. Striano

Research output: Contribution to journalArticle

Abstract

The A. have retrospectively evaluated long-term efficacy and tolerability of GVG as add-on therapy on 220 drug-resistant epileptic pts. After a follow-up ranging from 1 to 6 years, 38% are resulted responders, of which 9% are seizure-free and an additional 15% have achieved a greater than 75% reduction in seizure frequency (good-responders). This group of good- responders pts. is not significantly different from the remaining pts. regarding sex, age, age at onset of seizures, type and frequency of seizures, etiology of epileptic syndrome, number and type of associated AEDs. The only suggestive features are a shorter duration of illness in the good-responders group and the already known effectiveness of GVG in Tuberous Sclerosis. Thus the outcome of GVG treatment is still unpredictable and its efficacy should be verified for each patient.

Original languageItalian
Pages (from-to)131-132
Number of pages2
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number102-103
Publication statusPublished - 1998

Fingerprint

Vigabatrin
Seizures
Retrospective Studies
Tuberous Sclerosis
Age of Onset
Epilepsy
Therapeutics
Pharmaceutical Preparations
Drug Resistant Epilepsy

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

II vigabatrin in 'add-on' nelle epilessie farmacoresistenti. Sette anni di esperienza : Studio retrospettivo su 220 casi. / Mariniello, A.; Morena, S.; Loreto, V.; Muraca, B.; Nocerino, C.; Bilo, L.; Meo, R.; Ruosi, P.; Estraneo, A.; Mecarelli, O.; De Feo, M. R.; Striano, S.

In: Bollettino - Lega Italiana contro l'Epilessia, No. 102-103, 1998, p. 131-132.

Research output: Contribution to journalArticle

Mariniello, A, Morena, S, Loreto, V, Muraca, B, Nocerino, C, Bilo, L, Meo, R, Ruosi, P, Estraneo, A, Mecarelli, O, De Feo, MR & Striano, S 1998, 'II vigabatrin in 'add-on' nelle epilessie farmacoresistenti. Sette anni di esperienza: Studio retrospettivo su 220 casi', Bollettino - Lega Italiana contro l'Epilessia, no. 102-103, pp. 131-132.
Mariniello, A. ; Morena, S. ; Loreto, V. ; Muraca, B. ; Nocerino, C. ; Bilo, L. ; Meo, R. ; Ruosi, P. ; Estraneo, A. ; Mecarelli, O. ; De Feo, M. R. ; Striano, S. / II vigabatrin in 'add-on' nelle epilessie farmacoresistenti. Sette anni di esperienza : Studio retrospettivo su 220 casi. In: Bollettino - Lega Italiana contro l'Epilessia. 1998 ; No. 102-103. pp. 131-132.
@article{14ee3eadc5b74e22845a31304eba5f33,
title = "II vigabatrin in 'add-on' nelle epilessie farmacoresistenti. Sette anni di esperienza: Studio retrospettivo su 220 casi",
abstract = "The A. have retrospectively evaluated long-term efficacy and tolerability of GVG as add-on therapy on 220 drug-resistant epileptic pts. After a follow-up ranging from 1 to 6 years, 38{\%} are resulted responders, of which 9{\%} are seizure-free and an additional 15{\%} have achieved a greater than 75{\%} reduction in seizure frequency (good-responders). This group of good- responders pts. is not significantly different from the remaining pts. regarding sex, age, age at onset of seizures, type and frequency of seizures, etiology of epileptic syndrome, number and type of associated AEDs. The only suggestive features are a shorter duration of illness in the good-responders group and the already known effectiveness of GVG in Tuberous Sclerosis. Thus the outcome of GVG treatment is still unpredictable and its efficacy should be verified for each patient.",
keywords = "Drug-resistant Epilepsies, Long-term Follow-up, Vigabatrin",
author = "A. Mariniello and S. Morena and V. Loreto and B. Muraca and C. Nocerino and L. Bilo and R. Meo and P. Ruosi and A. Estraneo and O. Mecarelli and {De Feo}, {M. R.} and S. Striano",
year = "1998",
language = "Italian",
pages = "131--132",
journal = "Bollettino - Lega Italiana contro l'Epilessia",
issn = "0394-560X",
publisher = "Lega Italiana contro l'Epilessia",
number = "102-103",

}

TY - JOUR

T1 - II vigabatrin in 'add-on' nelle epilessie farmacoresistenti. Sette anni di esperienza

T2 - Studio retrospettivo su 220 casi

AU - Mariniello, A.

AU - Morena, S.

AU - Loreto, V.

AU - Muraca, B.

AU - Nocerino, C.

AU - Bilo, L.

AU - Meo, R.

AU - Ruosi, P.

AU - Estraneo, A.

AU - Mecarelli, O.

AU - De Feo, M. R.

AU - Striano, S.

PY - 1998

Y1 - 1998

N2 - The A. have retrospectively evaluated long-term efficacy and tolerability of GVG as add-on therapy on 220 drug-resistant epileptic pts. After a follow-up ranging from 1 to 6 years, 38% are resulted responders, of which 9% are seizure-free and an additional 15% have achieved a greater than 75% reduction in seizure frequency (good-responders). This group of good- responders pts. is not significantly different from the remaining pts. regarding sex, age, age at onset of seizures, type and frequency of seizures, etiology of epileptic syndrome, number and type of associated AEDs. The only suggestive features are a shorter duration of illness in the good-responders group and the already known effectiveness of GVG in Tuberous Sclerosis. Thus the outcome of GVG treatment is still unpredictable and its efficacy should be verified for each patient.

AB - The A. have retrospectively evaluated long-term efficacy and tolerability of GVG as add-on therapy on 220 drug-resistant epileptic pts. After a follow-up ranging from 1 to 6 years, 38% are resulted responders, of which 9% are seizure-free and an additional 15% have achieved a greater than 75% reduction in seizure frequency (good-responders). This group of good- responders pts. is not significantly different from the remaining pts. regarding sex, age, age at onset of seizures, type and frequency of seizures, etiology of epileptic syndrome, number and type of associated AEDs. The only suggestive features are a shorter duration of illness in the good-responders group and the already known effectiveness of GVG in Tuberous Sclerosis. Thus the outcome of GVG treatment is still unpredictable and its efficacy should be verified for each patient.

KW - Drug-resistant Epilepsies

KW - Long-term Follow-up

KW - Vigabatrin

UR - http://www.scopus.com/inward/record.url?scp=0032456452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032456452&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0032456452

SP - 131

EP - 132

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

SN - 0394-560X

IS - 102-103

ER -